Role of purine metabolism in chemoresistance
嘌呤代谢在化疗耐药中的作用
基本信息
- 批准号:10650311
- 负责人:
- 金额:$ 34.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ADP-Ribosylation FactorsAccountabilityAcidsAftercareAlkylating AgentsAlkylationAmino AcidsAnabolismBloodBrainBrain NeoplasmsCell ProliferationCell divisionCellsCharacteristicsChemoresistanceCiliaClustered Regularly Interspaced Short Palindromic RepeatsCytoprotectionDNADNA DamageDNA lesionDataDiagnosisDiseaseEffectivenessEngraftmentEnzymesExcisionFDA approvedGlioblastomaGliomaGoalsImmunoprecipitationIn VitroInosine MonophosphateIsotopesKineticsKnock-outMaintenanceMalignant NeoplasmsMalignant neoplasm of brainMammalian CellMapsMass Spectrum AnalysisMetabolicMycophenolateNerveNormal CellNucleotidesOperative Surgical ProceduresOxidoreductasePathway interactionsPatientsPermeabilityPharmaceutical PreparationsPhysiologicalProcessPrognosisProliferatingProtein FamilyProtein IsoformsProteinsProtocols documentationPurine NucleotidesPurinesRNARadiation therapyRecurrenceRecurrent tumorRecyclingRegulationRelapseReportingResistanceRoleSamplingSurface Plasmon ResonanceSystemTestingTherapeuticTherapeutic InterventionTimeblood-brain barrier permeabilizationcancer cellcancer stem cellchemotherapyclinically significantconventional therapycytotoxiceffective therapyfallsimprovedin vivoinsightknock-downmembermycophenolate mofetilnovelnovel strategiesnucleotide metabolismpatient derived xenograft modelpatient prognosispreventprotein protein interactionpurine metabolismresponsesmall moleculestable isotopestandard carestem cell biologystem cellstemozolomidetherapeutically effectivetherapy resistanttranslational therapeuticstreatment responsetumor
项目摘要
PROJECT SUMMARY
Glioblastoma (GBM), a grade IV tumor, is one of the most aggressive and infiltrative forms of brain cancer.
Patients that are currently diagnosed with Glioblastoma (GBM) have a very poor prognosis. Median survival is
around 8-10 months even after the standard care protocol of surgical resection followed by alkylating
chemotherapy (typically temozolomide or TMZ) and radiotherapy. This is because in nearly all patients the tumor
recurs after treatment since GBM cell can become resistant to therapy. Our goal is to develop a treatment for
GBM that will reduce recurrence rate and thereby improve the prognosis for patients. One of the distinguishing
characteristics of cancer is its uncontrolled cell division. Since cancer cells divide more rapidly than normal cells,
they require more purines, the building blocks of DNA and RNA. (The purine biosynthesis pathway has previously
been implicated in resistance to chemotherapy). Purines are either synthesized from amino acids and other small
molecules through the de novo biosynthesis pathway or are recycled from the microenvironment through the
salvage pathway. Cancer cells typically use the de novo biosynthesis pathway, whereas the central nerves
system usually rely more on the salvage pathway. Through initial analysis, we have identified ARL13B as a novel
regulator of the purine biosynthesis pathway during chemotherapy. ARL13B, a member of the ADP-ribosylation
factor-like family protein accountable for cilia maintenance, directly interacts with inosine monophosphate
dehydrogenase 2 (IMPDH2), the rate-limiting enzyme purine biosynthesis. In our initial studies knocking-down
ARL13B inhibited GBM cells’ utilization of the de novo pathway after TMZ treatment and increased utilization of
the salvage biosynthesis pathway. The effectiveness of TMZ treatment was also elevated in vitro and in vivo
following ARL13B knockdown. We therefore hypothesize that the ARL13B-IMPDH2 regulated switch from the
salvage pathway to the de novo purine biosynthesis pathway is necessary for GBM cells’ adaptation to alkylating-
based chemotherapy. The goal of this study is to further investigate this hypothesis through the following aims:
1) examine the role of ARL13B in regulating purine metabolism; 2) elucidate the role of purine metabolism in
promoting resistance to TMZ; 3) modulate the purine biosynthesis pathway to overcome the resistance against
the alkylating-based chemotherapy. Overall, we hope to gain novel insight into the role of purine metabolism in
GBM in the context of therapeutic resistance with the end goal of developing a translational therapy to prevent
GBM recurrence.!
项目摘要
胶质母细胞瘤(GBM)是一种IV级肿瘤,是最具侵袭性和浸润性的脑癌之一。
目前诊断为胶质母细胞瘤(GBM)的患者预后非常差。中位生存期
即使在手术切除然后烷基化的标准护理方案之后,
化疗(通常为替莫唑胺或TMZ)和放疗。这是因为在几乎所有的患者中,
治疗后复发,因为GBM细胞可能对治疗产生抗性。我们的目标是开发一种治疗方法,
GBM将降低复发率,从而改善患者的预后。其中一个区别
癌症的特征是其不受控制的细胞分裂。由于癌细胞比正常细胞分裂得更快,
它们需要更多的嘌呤,DNA和RNA的基本组成部分。(The嘌呤生物合成途径以前
与化疗耐药性有关)。嘌呤是由氨基酸和其他小分子合成的。
分子通过从头生物合成途径或从微环境中再循环,
补救途径癌细胞通常使用从头生物合成途径,而中枢神经
系统通常更多地依赖于救助途径。通过初步分析,我们确定ARL 13 B是一个新的
化疗期间嘌呤生物合成途径的调节剂。ARL 13 B,ADP核糖基化成员
负责纤毛维持的因子样家族蛋白,直接与肌苷一磷酸相互作用
脱氢酶2(IMPDH 2),嘌呤生物合成的限速酶。在我们最初的研究中,
ARL 13 B抑制TMZ处理后GBM细胞对从头途径的利用,并增加TMZ处理后GBM细胞对
补救生物合成途径。TMZ治疗的有效性在体外和体内也有所提高
在ARL 13 B敲除之后。因此,我们假设ARL 13 B-IMPDH 2调节的从细胞外基质的转换,
从补救途径到从头嘌呤生物合成途径是GBM细胞适应烷基化所必需的。
基础化疗。本研究的目的是通过以下目的进一步研究这一假设:
1)研究ARL 13 B在调节嘌呤代谢中的作用; 2)阐明嘌呤代谢在
促进对TMZ的抗性; 3)调节嘌呤生物合成途径以克服对TMZ的抗性。
烷基化化疗总之,我们希望获得新的见解嘌呤代谢的作用,
GBM在治疗耐药性的背景下,最终目标是开发一种转化疗法,
GBM复发!
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Separate and not equal: sex differences in JAM-A tumor suppression in glioblastoma.
独立而不相等:胶质母细胞瘤中 JAM-A 肿瘤抑制的性别差异。
- DOI:10.1093/neuonc/noaa218
- 发表时间:2020
- 期刊:
- 影响因子:15.9
- 作者:Shireman,JackM;Ahmed,AtiqueU
- 通讯作者:Ahmed,AtiqueU
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Atique U. Ahmed其他文献
Glioblastoma recurrence and the role of MGMT promoter methylation
胶质母细胞瘤复发和 MGMT 启动子甲基化的作用
- DOI:
10.1101/317636 - 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
K. Storey;K. Leder;A. Hawkins;K. Swanson;Atique U. Ahmed;R. Rockne;J. Foo - 通讯作者:
J. Foo
Beyond the brain: exploring the impact of animal models of leptomeningeal disease from solid tumors
- DOI:
10.1186/s40478-025-01959-4 - 发表时间:
2025-05-19 - 期刊:
- 影响因子:5.700
- 作者:
Jillyn R. Turunen;Priya Kumthekar;Atique U. Ahmed - 通讯作者:
Atique U. Ahmed
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY
实验治疗学和药理学
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:0
- 作者:
C. Aaberg;Louise Fogh;Bo Halle;V. Jensen;N. Brünner;B. Kristensen;T. Abe;Y. Momii;J. Watanabe;I. Morisaki;A. Natsume;T. Wakabayashi;M. Fujiki;Beatriz Aldaz;A. Fabius;J. Silber;Girish Harinath;T. Chan;J. Huse;S. Anai;T. Hide;Hideo Nakamura;K. Makino;S. Yano;J. Kuratsu;I. Balyasnikova;M. Prasol;Deepak K. Kanoija;K. Aboody;M. Lesniak;T. Barone;C. Burkhart;A. Purmal;A. Gudkov;K. Gurova;R. Plunkett;K. Barton;Katherine L. Misuraca;Francisco J. Cordero;E. Dobrikova;H. Min;M. Gromeier;D. Kirsch;O. Becher;L. B. Pont;J. Kloezeman;M. Bent;R. Kanaar;A. Kremer;S. Swagemakers;P. French;C. Dirven;M. Lamfers;S. Leenstra;R. Balvers;A. Kleijn;S. Lawler;X. Gong;A. Andres;Joseph A. Hanson;J. Delashaw;D. Bota;Chiao;N. Yao;W. Chuang;Chen Chang;Pin;Chiung;Kuo;Yuhu Cheng;Qing;R. Morshed;Yu Han;B. Auffinger;D. Wainwright;Lingjiao Zhang;Alex L. Tobias;E. Rincon;B. Thaci;Atique U. Ahmed;Chuang He;Young A. Choi;Hetal Pandya;D. Gibo;Isabela Fokt;W. Priebe;W. Debinski;Yevgen Chornenkyy;S. Agnihotri;P. Buczkowicz;P. Rakopoulos;A. Morrison;M. Barszczyk;C. Hawkins;Sylvia A. Chung;S. Decollogne;Peter P. Luk;Han Shen;Wendy Ha;B. Day;B. Stringer;P. Hogg;P. Dilda;K. McDonald;S. Moore;M. Hayden;J. Bergen;YouRong S. Su;H. Rayburn;M. Edwards;M. Scott;J. Cochran;Arabinda Das;A. Varma;G. Wallace;Yaenette N. Dixon;W. A. Vandergrift;P. Giglio;S. Ray;Sunil J. Patel;N. Banik;T. Dasgupta;A. Olow;Xiaodong Yang;S. Mueller;M. Prados;C. James;D. Haas;Nimita Dave;P. Desai;G. Gudelsky;L. Chow;K. LaSance;X. Qi;J. Driscoll;K. Ebsworth;M. Walters;L. Ertl;Yu Wang;Robert D. Berahovic;J. McMahon;J. Powers;J. Jaén;T. Schall;Z. Eroglu;J. Portnow;Arianne D. Sacramento;Elizabeth Garcia;A. Raubitschek;T. Synold;S. Esaki;S. Rabkin;R. Martuza;H. Wakimoto;S. Ferluga;C. M. L. Tomé;H. Førde;I. A. Netland;L. Sleire;B. Skeie;P. Enger;D. Goplen;M. Giladi;A. Tichon;R. Schneiderman;Y. Porat;M. Munster;Matan Dishon;U. Weinberg;E. Kirson;Yoram Wasserman;Y. Palti;D. Gramatzki;M. Staudinger;K. Frei;M. Peipp;M. Weller;C. Grasso;Lining Liu;Noah E. Berlow;L. Davis;M. Fouladi;A. Gajjar;Elaine C. Huang;E. Hulleman;M. Hutt;C. Keller;Xiao;P. Meltzer;Martha Quezado;M. Quist;Eric H. Raabe;P. Spellman;Nathalène Truffaux;Dannis van Vurden;Nicholas J. Wang;K. Warren;R. Pal;J. Grill;Michelle Monje;A. Green;S. Ramkissoon;D. McCauley;K. Jones;J. Perry;L. Ramkissoon;C. Maire;S. Shacham;K. Ligon;A. Kung;Katarzyna Zielinska;V. Grozman;J. Tu;K. Viktorsson;R. Lewensohn;Shiv K. Gupta;Ann C Mladek;K. Bakken;B. Carlson;F. Boakye;S. Kizilbash;M. Schroeder;J. Reid;J. Sarkaria;P. Hadaczek;T. Ozawa;L. Soroceanu;Y. Yoshida;Lisa Matlaf;Eric Singer;Estefania Fiallos;C. Cobbs;R. Hashizume;M. Tom;Yuichiro Ihara;R. Santos;J. D. L. Torre;Edgar L. Lepe;T. Waldman;D. James;Xi Huang;Lu Yu;N. Gupta;D. Solomon;Zhiguo Zhang;Takuro Hayashi;K. Adachi;S. Nagahisa;M. Hasegawa;Y. Hirose;M. Gephart;YouRong S. Su;Shawn D. Hingtgen;Randa Kasmieh;Irina Nesterenko;Jose;R. Dash;D. Sarkar;P. Fisher;K. Shah;Eric A. Horne;P. Diaz;N. Stella;Hongwei Yang;Tiffany T. Huang;J. Hlavaty;Derek Ostertag;Fernando Lopez Espinoza;B. Martin;H. Petznek;Maria E. Rodriguez;C. Ibañez;N. Kasahara;W. Günzburg;H. Gruber;D. Pertschuk;D. Jolly;J. Robbins;B. Hurwitz;J. Yoo;Chelsea M Bolyard;Jun‐ge Yu;Jeffery Wojton;Jianying Zhang;Zachary Bailey;D. Eaves;T. Cripe;M. Old;B. Kaur;L. Serwer;N. L. Moan;Sarah W S Ng;N. Butowski;A. Krtolica;S. Cary;T. Johns;S. Greenall;J. Donoghue;T. Adams;G. Karpel;M. Westhoff;R. Kast;A. Dwucet;C. Wirtz;K. Debatin;M. Halatsch;N. Merkur;Forrest M. Kievit;Zachary Stephen;Kui Wang;D. Kolstoe;J. Silber;R. Ellenbogen;Miqin Zhang;G. Kitange;Erik S. Haefner;Kristina H. Knubel;Ben M. Pernu;A. Sufit;Angela M Pierce;Sarah Nelson;A. Keating;S. S. Jensen;B. Kristensen;J. Lachowicz;M. Demeule;A. Régina;S. Tripathy;J. Curry;T. Nguyen;J. Castaigne;Tina N. Davis;A. Davis;Kevin Tanaka;T. Keating;Jennifer A. Getz;G. Kapp;J. M. Romero;Sang Y Lee;Srinivasa R. Ramisetti;Becky Slagle;Arun Sharma;J. Connor;Wen‐Shin Lee;M. Kluk;J. Aster;K. Ligon;Stella Sun;Derek Lee;A. Ho;J. Pu;Ziao Zhang;N. Lee;P. Day;G. Leung;Zhiguo Liu;Xiaoli Liu;A. Madhankumar;P. Miller;B. Webb;J. Connor;Qing X. Yang;Merryl R. Lobo;Sarah Green;M. Schabel;Y. Gillespie;R. Woltjer;M. Pike;Yu;J. D. L. Torre;H. A. Luchman;O. Stechishin;Stephanie A Nguyen;J. Cairncross;S. Weiss;X. Lun;J. Wells;X. Hao;Jun Zhang;Natalie Grinshtein;David L. Kaplan;Artee Luchman;D. Senger;S. Robbins;A. Madhankumar;Elias B Rizk;Russell Payne;Annie Park;Min Pang;K. Harbaugh;Anette Wilisch;D. Pachow;E. Kirches;C. Mawrin;S. Mcdonell;Ji Liang;Y. Piao;N. Nguyen;A. Yung;R. Verhaak;E. Sulman;C. Stephan;F. Lang;J. Groot;Yoshihumi Mizobuchi;Toshiyuki Okazaki;T. Kageji;Kazuyuki Kuwayama;K. Kitazato;H. Mure;Keijiro Hara;R. Morigaki;K. Matsuzaki;Kohei Nakajima;S. Nagahiro;S. Kumala;M. Heravi;S. Dević;T. Muanza;Kristina H. Knubel;A. Neuwelt;Tam Nguyen;Y. J. Wu;A. Donson;Rajeev Vibhakar;Sujatha Venkatamaran;V. Amani;E. Neuwelt;L. Rapkin;N. Foreman;Fady Ibrahim;P. New;K. Cui;Hong Zhao;D. Chow;W. Stephen;Kyoko Nozue;M. Nagane;K. McDonald;D. Ogawa;E. Chiocca;J. Godlewski;Akshal S. Patel;Nagarekha Pasupuleti;F. Gorin;Anthony Valenzuela;Leonardo J. Leon;K. Carraway;Chepapil Ramachandran;S. Nair;Karl;Z. Khatib;E. Escalon;S. Melnick;Andrew Phillips;E. Boghaert;Kedar S Vaidya;P. Ansell;D. Shalinsky;Yumin Zhang;Martin J. Voorbach;Sarah R. Mudd;K. Holen;R. Humerickhouse;E. Reilly;S. Parab;Oscar R. Diago;D. Jolly;T. Ryken;Supreet Agarwal;M. Al;M. Alqudah;Zita A. Sibenaller;Mahfoud Assemolt;K. Sai;Wen;Weiping Li;Zhongwu Chen;R. Saito;Y. Sonoda;Masayuki Kanamori;Y. Yamashita;T. Kumabe;T. Tominaga;G. Sarkar;G. Curran;R. Jenkins;R. Scharnweber;Yuki Kato;Jeff Lin;R. Everson;H. Soto;C. Kruse;L. Liau;R. Prins;Samantha L Semenkow;Q. Chu;C. Eberhart;Rajarshi Sengupta;J. Marassa;D. Piwnica;J. Rubin;R. Shai;Tatyana Pismenyuk;Itai Moshe;Tamar Fisher;Shani Freedman;A. Simon;N. Amariglio;G. Rechavi;A. Toren;M. Yalon;Y. Shimazu;K. Kurozumi;T. Ichikawa;K. Fujii;Manabu Onishi;Joji Ishida;T. Oka;Masami Watanabe;Y. Nasu;H. Kumon;I. Date;R. Sirianni;Rebecca L. McCall;J. Spoor;M. V. D. Kaaij;Mieke Geurtjens;Omid Veiseh;Chen Fang;M. Leung;G. Strohbehn;K. Atsina;T.R. Patel;J. Piepmeier;Jiangbing Zhou;W. Saltzman;Masamichi Takahashi;G. Valdes;Akihito Inagaki;Shuichi Kamijima;K. Hiraoka;E. Micewicz;W. McBride;K. Iwamoto;C. McCully;J. Bacher;T. Thomas;R. Murphy;E. Steffen;R. Mcallister;Devang Pastakia;B. Widemann;H. Yang;M. Hua;Hao;Eric C. Woolf;M. Abdelwahab;Kathryn E. Fenton;Qingwei Liu;G. Turner;M. Preul;A. Scheck;W. Shen;Dennis Brown;H. Pedersen;Jie Zhang;S. Hariono;Tsun‐Wen Yao;Angadpreet Sidhu;W. Weiss;T. Nicolaides;Temidayo O B Olusanya - 通讯作者:
Temidayo O B Olusanya
Interaction between DNA damage response, translation and apoptosome determines cancer susceptibility to TOP2 poisons
DNA 损伤反应、翻译和凋亡体之间的相互作用决定了癌症对 TOP2 毒物的易感性
- DOI:
10.1101/614024 - 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Chidiebere U. Awah;Li Chen;M. Bansal;A. Mahajan;Jan Winter;Meeki K. Lad;L. Warnke;E. González;Cheol Park;Zhang Daniel;Eric Feldstein;Dou Yu;Markella Zannikou;I. Balyasnikova;Regina T. Martuscello;Silvana Konerman;Balázs Győrffy;K. Burdett;D. Scholtens;R. Stupp;Atique U. Ahmed;P. Hsu;A. Sonabend - 通讯作者:
A. Sonabend
Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma
多巴胺受体 2 (DRD2) 的激活促进胶质母细胞瘤的转录组和代谢可塑性
- DOI:
10.1101/454389 - 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Seamus Caragher;Jack M. Shireman;Mei Huang;J. Miska;Cheol Shivani Baisiwala;Hong Park;Miranda R Saathoff;L. Warnke;Ting Xiao;M. Lesniak;David James;H. Meltzer;A. Tryba;Atique U. Ahmed - 通讯作者:
Atique U. Ahmed
Atique U. Ahmed的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Atique U. Ahmed', 18)}}的其他基金
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma
霉酚酸酯(MMF)联合替莫唑胺(TMZ)治疗新诊断胶质母细胞瘤患者的 1 期适应性剂量递增研究
- 批准号:
10478885 - 财政年份:2018
- 资助金额:
$ 34.56万 - 项目类别:
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma
霉酚酸酯联合替莫唑胺治疗新诊断胶质母细胞瘤患者的 1 期适应性剂量递增研究
- 批准号:
10626396 - 财政年份:2018
- 资助金额:
$ 34.56万 - 项目类别:
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma
霉酚酸酯(MMF)联合替莫唑胺(TMZ)治疗新诊断胶质母细胞瘤患者的 1 期适应性剂量递增研究
- 批准号:
10468354 - 财政年份:2018
- 资助金额:
$ 34.56万 - 项目类别:
Cellular Plasticity and equilibrium in GBM Progression
GBM 进展中的细胞可塑性和平衡
- 批准号:
10666657 - 财政年份:2017
- 资助金额:
$ 34.56万 - 项目类别:
Cellular Plasticity and equilibrium in GBM Progression
GBM 进展中的细胞可塑性和平衡
- 批准号:
10539645 - 财政年份:2017
- 资助金额:
$ 34.56万 - 项目类别:
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas
基于基因修饰的神经干细胞的病毒疗法治疗侵袭性胶质瘤
- 批准号:
9262538 - 财政年份:2013
- 资助金额:
$ 34.56万 - 项目类别:
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas
基于基因修饰的神经干细胞的病毒疗法治疗侵袭性胶质瘤
- 批准号:
8725602 - 财政年份:2013
- 资助金额:
$ 34.56万 - 项目类别:
相似海外基金
CRII: SaTC: Privacy vs. Accountability--Usable Deniability and Non-Repudiation for Encrypted Messaging Systems
CRII:SaTC:隐私与责任——加密消息系统的可用否认性和不可否认性
- 批准号:
2348181 - 财政年份:2024
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant
Attribution of Machine-generated Code for Accountability
机器生成代码的责任归属
- 批准号:
DP240102164 - 财政年份:2024
- 资助金额:
$ 34.56万 - 项目类别:
Discovery Projects
Global Governing Gaps and Accountability Traps for Solar Energy and Storage
太阳能和存储的全球治理差距和问责陷阱
- 批准号:
DP230103043 - 财政年份:2024
- 资助金额:
$ 34.56万 - 项目类别:
Discovery Projects
Collaborative Research: U.S. institutions after COVID-19: Trust, accountability, and public perceptions
合作研究:COVID-19 后的美国机构:信任、责任和公众看法
- 批准号:
2422394 - 财政年份:2024
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant
Collaborative Research: The Architecture of Accountability in 21st Century Latin America
合作研究:21 世纪拉丁美洲的问责架构
- 批准号:
2314749 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant
Ethical Industry 4.0: Embedding Legality, Integrity and Accountability in Digital Manufacturing Ecosystems
道德工业 4.0:将合法性、诚信和责任融入数字制造生态系统
- 批准号:
2412678 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant
Conference: Understanding Democracy, Elections, and Political Accountability
会议:了解民主、选举和政治责任
- 批准号:
2321010 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant
The Tipuna Project: Intergenerational Healing, Settler Accountability and Decolonising Participatory Action Research in Aotearoa
Tipuna 项目:新西兰的代际疗愈、定居者责任和非殖民化参与行动研究
- 批准号:
AH/X008223/1 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Research Grant
Collaborative Research: SaTC: CORE: Small: Accountability for Central Bank Digital Currency
协作研究:SaTC:核心:小型:中央银行数字货币的责任
- 批准号:
2325477 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Continuing Grant
DASS: A Multi-level Collaborative Design Framework for Cross-sovereignty Software Accountability
DASS:跨主权软件责任的多层次协作设计框架
- 批准号:
2317086 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Standard Grant